What the abstracts report for modafinil adhd
For modafinil adhd, the first abstract says the team searched for trials that compared several drugs with each other or placebo.
The same abstract says amphetamines, methylphenidate, bupropion, and atomoxetine were better than placebo in adults. These were clinicians' ratings. The abstract says modafinil was not better than placebo in adults.
In children and adolescents, on clinician ratings closest to 12 weeks, all included drugs did better than placebo.
For children and teens, teachers' ratings show only methylphenidate and modafinil did better than placebo.
The abstract also says modafinil was less well tolerated than placebo in adults only. 4·01 is the odds ratio for dropping out because of side effects, and 1·42 to 11·33 is its 95% range.
The first abstract says the study is registered with PROSPERO, number CRD42014008976.
The second abstract lists the drugs it included. Modafinil is one of them.
That abstract says eighty-one unique trials were included. It says most of them were at high or unclear risk of at least one important source of bias.
It also says the certainty of the evidence was very low to low for all outcomes. It says there was limited reporting of long-term adverse events.
Summary of the abstract. The full paper was not read.
Sources
- pubmed-30097390 retrieved 2026-11-18 PMID 30097390
- pubmed-33085721 retrieved 2026-11-18 PMID 33085721